Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25325413 | 1.00 | RIPK1 (0.36) | RIPK1PRMT5WDR77OPRM1OPRK1 | |
| SCHEMBL25918545 | 0.88 | RORC (0.33) | — | |
| SCHEMBL25327211 | 0.84 | PRMT5 (0.39) | RIPK1PRMT5WDR77SIGMAR1P2RX7 | |
| SCHEMBL25324212 | 0.84 | RIPK1 (0.39) | RIPK1PRMT5WDR77NR1H2NR1H3 | |
| SCHEMBL25324288 | 0.83 | POLB (0.45) | RIPK1PRMT5WDR77OPRM1OPRK1 | |
| SCHEMBL25326238 | 0.81 | PRMT5 (0.36) | RIPK1PRMT5WDR77OPRM1OPRK1 | |
| SCHEMBL25326234 | 0.81 | PRMT5 (0.36) | RIPK1PRMT5WDR77OPRM1OPRK1 | |
| SCHEMBL25916906 | 0.81 | TSHR (0.36) | — | |
| SCHEMBL25327781 | 0.80 | NR1H2 (0.45) | RIPK1NR1H2NR1H3 | |
| SCHEMBL25327358 | 0.80 | RIPK1 (0.44) | RIPK1PRMT5WDR77SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | RIPK1 4782/4885PRMT5 2082/4885WDR77 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.